Off-Label Use of Biologics for IMIDs
Dr. Erin Boh says understanding disease pathophysiology provides treatment option insights for immune mediated inflammatory diseases that do not have FDA-approved therapies. According to dermatologist Erin E. Boh, MD, PhD, understanding disease pathophysiology is key to treating immune mediated inflammatory diseases (IMIDs) that do not have efficacious, FDA-approved therapies. In her presentation, “Off Label Use […]
Cemiplimab just approved for locally advanced and metastatic basal cell carcinoma
On February 9, 2021, the Food and Drug Administration granted regular approval to cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate and granted accelerated approval to cemiplimab-rwlc for patients with metastatic BCC (mBCC) […]